Influential cancer group rolls out first set of 'affordability' ratings on cancer drugs

The National Comprehensive Cancer Network unveiled its first set of "evidence blocks" that include cost information on oncology drugs; this first round focuses on chronic myelogenous leukemia (CML) and multiple myeloma. Drugs from Bristol-Myers Squibb ($BMY), Novartis ($NVS), Johnson & Johnson ($JNJ), and Celgene ($CELG), among others, were assessed on efficacy, safety and affordability. More from FiercePharmaMarketing

Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.